Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m(2)), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation base...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Dhakal, Binod, D’Souza, Anita, Hamadani, Mehdi, Arce-Lara, Carlos, Schroeder, Katrina, Chhabra, Saurabh, Shah, Nirav N., Gauger, Katelyn, Keaton, Taylor, Pasquini, Marcelo, Hari, Parameswaran
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6663939/
https://ncbi.nlm.nih.gov/pubmed/31358733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0219-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars